Caribou Biosciences, Inc.

Healthcare · Biotechnology · United States

Last price 0.445 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 47.71M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA genome-editing technology that enables precise genome editing of allogeneic cell therapies. The company develops Vispacabtagene Regedleucel, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCM...